ALK and lung carcinoma: Next, mice subcutaneously injected with H1299 control (without RNase1 expression), RDAA (ALK and RNase1 co-expression), or ALK mut lung cancer cells (EML4-ALK expression) were treated with ceritinib for two weeks (25 mg/kg/day).